These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

859 related items for PubMed ID: 28871396

  • 1. Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer.
    Venderink W, van der Leest M, van Luijtelaar A, van de Ven WJM, Fütterer JJ, Sedelaar JPM, Huisman HJ.
    World J Urol; 2017 Dec; 35(12):1849-1855. PubMed ID: 28871396
    [Abstract] [Full Text] [Related]

  • 2. Yield of Repeat Targeted Direct in-Bore Magnetic Resonance-Guided Prostate Biopsy (MRGB) of the Same Lesions in Men Having a Prior Negative Targeted MRGB.
    Venderink W, Jenniskens SF, Michiel Sedelaar JP, Tamada T, Fütterer JJ.
    Korean J Radiol; 2018 Dec; 19(4):733-741. PubMed ID: 29962879
    [Abstract] [Full Text] [Related]

  • 3. 3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy.
    Hosseiny M, Shakeri S, Felker ER, Lu D, Sayre J, Ahuja P, Raman SS.
    AJR Am J Roentgenol; 2020 Sep; 215(3):660-666. PubMed ID: 32755166
    [Abstract] [Full Text] [Related]

  • 4. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis.
    Choi YH, Kang MY, Sung HH, Jeon HG, Chang Jeong B, Seo SI, Jeon SS, Kim CK, Park BK, Lee HM.
    Clin Genitourin Cancer; 2019 Feb; 17(1):e19-e25. PubMed ID: 30415878
    [Abstract] [Full Text] [Related]

  • 5. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer.
    Stabile A, Dell'Oglio P, De Cobelli F, Esposito A, Gandaglia G, Fossati N, Brembilla G, Cristel G, Cardone G, Deho' F, Losa A, Suardi N, Gaboardi F, Del Maschio A, Montorsi F, Briganti A.
    Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225
    [Abstract] [Full Text] [Related]

  • 6. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study.
    van der Leest M, Cornel E, Israël B, Hendriks R, Padhani AR, Hoogenboom M, Zamecnik P, Bakker D, Setiasti AY, Veltman J, van den Hout H, van der Lelij H, van Oort I, Klaver S, Debruyne F, Sedelaar M, Hannink G, Rovers M, Hulsbergen-van de Kaa C, Barentsz JO.
    Eur Urol; 2019 Apr; 75(4):570-578. PubMed ID: 30477981
    [Abstract] [Full Text] [Related]

  • 7. Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions.
    Yaxley AJ, Yaxley JW, Thangasamy IA, Ballard E, Pokorny MR.
    BJU Int; 2017 Nov; 120 Suppl 3():43-50. PubMed ID: 28749035
    [Abstract] [Full Text] [Related]

  • 8. Is targeted magnetic resonance imaging/transrectal ultrasound fusion prostate biopsy enough for the detection of prostate cancer in patients with PI-RADS ≥3: Results of a prospective, randomized clinical trial.
    Zhang J, Zhu A, Sun D, Guo S, Zhang H, Liu S, Fu Q, Zhang K.
    J Cancer Res Ther; 2020 Nov; 16(7):1698-1702. PubMed ID: 33565519
    [Abstract] [Full Text] [Related]

  • 9. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
    Faiella E, Santucci D, Greco F, Frauenfelder G, Giacobbe V, Muto G, Zobel BB, Grasso RF.
    Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
    [Abstract] [Full Text] [Related]

  • 10. Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer.
    Stabile A, Dell'Oglio P, Gandaglia G, Fossati N, Brembilla G, Cristel G, Dehò F, Scattoni V, Maga T, Losa A, Gaboardi F, Cardone G, Esposito A, De Cobelli F, Del Maschio A, Montorsi F, Briganti A.
    Eur Urol Oncol; 2018 Jun; 1(2):120-128. PubMed ID: 31100235
    [Abstract] [Full Text] [Related]

  • 11. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy.
    Cash H, Maxeiner A, Stephan C, Fischer T, Durmus T, Holzmann J, Asbach P, Haas M, Hinz S, Neymeyer J, Miller K, Günzel K, Kempkensteffen C.
    World J Urol; 2016 Apr; 34(4):525-32. PubMed ID: 26293117
    [Abstract] [Full Text] [Related]

  • 12. Analysis of PI-RADS 4 cases: Management recommendations for negatively biopsied patients.
    Ullrich T, Arsov C, Quentin M, Laqua N, Klingebiel M, Martin O, Hiester A, Blondin D, Rabenalt R, Albers P, Antoch G, Schimmöller L.
    Eur J Radiol; 2019 Apr; 113():1-6. PubMed ID: 30927932
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of 3T Multiparametric MR Imaging followed by 3T in-Bore MR-Guided Biopsy for Detection of Clinically Significant Prostate Cancer Based on PIRADSv2.1 Score.
    Hosseiny M, Felker ER, Azadikhah A, Suvannarerg V, Sayre J, Ponzini D, Ahuja P, Lu D, Raman SS.
    J Vasc Interv Radiol; 2020 Oct; 31(10):1619-1626. PubMed ID: 32921565
    [Abstract] [Full Text] [Related]

  • 14. Prostate cancer detection in patients with prior negative biopsy undergoing cognitive-, robotic- or in-bore MRI target biopsy.
    Kaufmann S, Russo GI, Bamberg F, Löwe L, Morgia G, Nikolaou K, Stenzl A, Kruck S, Bedke J.
    World J Urol; 2018 May; 36(5):761-768. PubMed ID: 29380130
    [Abstract] [Full Text] [Related]

  • 15. Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results.
    Tewes S, Hueper K, Hartung D, Imkamp F, Herrmann TR, Weidemann J, Renckly S, Kuczyk MA, Wacker F, Peters I.
    World J Urol; 2015 Nov; 33(11):1707-14. PubMed ID: 25774003
    [Abstract] [Full Text] [Related]

  • 16. Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer.
    Venderink W, van Luijtelaar A, Bomers JGR, van der Leest M, Hulsbergen-van de Kaa C, Barentsz JO, Sedelaar JPM, Fütterer JJ.
    Eur Urol; 2018 Mar; 73(3):353-360. PubMed ID: 28258784
    [Abstract] [Full Text] [Related]

  • 17. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
    Kaufmann B, Saba K, Schmidli TS, Stutz S, Bissig L, Britschgi AJ, Schaeren E, Gu A, Langenegger N, Sulser T, Eberli D, Keller EX, Hermanns T, Poyet C.
    Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
    [Abstract] [Full Text] [Related]

  • 18. Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection.
    Mertan FV, Greer MD, Shih JH, George AK, Kongnyuy M, Muthigi A, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B.
    J Urol; 2016 Sep; 196(3):690-6. PubMed ID: 27101772
    [Abstract] [Full Text] [Related]

  • 19. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.
    Hoeks CM, Schouten MG, Bomers JG, Hoogendoorn SP, Hulsbergen-van de Kaa CA, Hambrock T, Vergunst H, Sedelaar JP, Fütterer JJ, Barentsz JO.
    Eur Urol; 2012 Nov; 62(5):902-9. PubMed ID: 22325447
    [Abstract] [Full Text] [Related]

  • 20. Value of 3-T multiparametric magnetic resonance imaging and magnetic resonance-guided biopsy for early risk restratification in active surveillance of low-risk prostate cancer: a prospective multicenter cohort study.
    Hoeks CM, Somford DM, van Oort IM, Vergunst H, Oddens JR, Smits GA, Roobol MJ, Bul M, Hambrock T, Witjes JA, Fütterer JJ, Hulsbergen-van de Kaa CA, Barentsz JO.
    Invest Radiol; 2014 Mar; 49(3):165-72. PubMed ID: 24220253
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.